Shopping Cart
Remove All
Your shopping cart is currently empty
ABBV-706 is an antibody-drug conjugate (ADC) that targets the receptor tyrosine kinase SEZ6. After binding to the surface of tumor cells, it is internalized and releases a cytotoxic payload, thereby inducing tumor cell death. ABBV-706 is currently in clinical development and has demonstrated potential antitumor activity in solid tumors such as small cell lung cancer.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $825 | 6-8 weeks | 6-8 weeks | |
| 5 mg | $2,060 | 6-8 weeks | 6-8 weeks | |
| 10 mg | $3,190 | 6-8 weeks | 6-8 weeks | |
| 50 mg | Inquiry | 6-8 weeks | 6-8 weeks |
| Description | ABBV-706 is an antibody-drug conjugate (ADC) that targets the receptor tyrosine kinase SEZ6. After binding to the surface of tumor cells, it is internalized and releases a cytotoxic payload, thereby inducing tumor cell death. ABBV-706 is currently in clinical development and has demonstrated potential antitumor activity in solid tumors such as small cell lung cancer. |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Storage | Store at -20°C Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.